Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study of 177Lu-JH040182 in Patients With FAP-Positive Malignancies
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
This first-in-human study aimed to assess the safety and internal radiation dosimetry of 177Lu-JH040182, a novel FAP-targeted radiopharmaceutical, in patients with FAP-positive tumors. All patients underwent screening via 68Ga-FAPI PET/CT. Those confirmed to have FAP-positive lesions on PET imaging received administration of 177Lu-JH040182, and serial-time-point SPECT images were acquired for internal radiation dosimetry calculations.
Official title: First-in-Human Safety and Dosimetry Study of ¹⁷⁷Lu-FAPI in Patients With FAP-Positive Malignancies
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
3
Start Date
2025-04-01
Completion Date
2027-12-31
Last Updated
2026-07-02
Healthy Volunteers
No
Interventions
177Lu-JH040182 with an activity of approximately 5.55-7.50 GBq
Subjects will receive intravenous administration of 177Lu-JH040182 at an activity of approximately 5.55-7.50 GBq.
Locations (1)
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China